CMG Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
CMG Pharmaceutical Co., Ltd.'s Market Cap is ₩617B. At end of 2025 it was ₩2752B. Ranked #1566 of 2,405 in KR market (top 65%), #916 of 1,627 on KOSDAQ (top 56%), #173 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 75%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 61.69B KRW | KR#1,566/2,405 Sec#173/231 |
| Revenue | 115.71B KRW | KR#1,334/2,405 Sec#85/231 |
| Net Income | 4.64B KRW | KR#1,243/2,405 Sec#86/231 |
| Total Assets | 320.07B KRW | KR#997/2,405 Sec#63/231 |
| Net Assets | 204.30B KRW | KR#929/2,405 Sec#65/231 |
| Employees | 282 | KR#836/2,405 Sec#70/231 |
| Value | ||
| P/E | 13.30x | KR#1,024/2,405 Sec#59/231 |
| P/B | 0.30x | KR#398/2,405 Sec#15/231 |
| P/S | 0.53x | KR#1,021/2,405 Sec#51/231 |
| FCF Yield | -65.89% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 2.27% | KR#1,381/2,405 Sec#94/231 |
| ROA | 1.45% | KR#1,318/2,405 Sec#94/231 |
| Op. Margin | -3.14% | KR#1,785/2,405 Sec#121/231 |
| Revenue Growth | 22.15% | KR#510/2,405 Sec#48/231 |
| Financial Health | ||
| Debt Ratio | 56.66% | KR#1,047/2,405 Sec#121/231 |
| Total Debt | 68.50B KRW | KR#874/2,405 Sec#59/231 |
| FCF | -40.65B KRW | KR#2,035/2,405 Sec#201/231 |
| Cash | 11.51B KRW | KR#1,616/2,405 Sec#137/231 |
| Current Ratio | 1.17x | KR#1,518/2,405 Sec#157/231 |
| Performance | ||
| 1Y Return | -76.93% | KR#2,327/2,405 Sec#225/231 |
| 1M Return | -25.49% | KR#2,105/2,405 Sec#209/231 |
| From 52W High | -81.11% | KR#2,306/2,405 Sec#212/231 |
| 1Y MDD | -80.54% | KR#2,284/2,405 Sec#202/231 |
| Trading | ||
| Volume | 49,292 shares | KR#978/2,405 Sec#104/231 |
| Trading Value | 203.0M KRW | KR#1,125/2,405 Sec#127/231 |
| Foreign Own. | 6.48% | KR#680/2,405 Sec#60/231 |
| Per Share | ||
| EPS | 313 KRW | KR#1,155/2,405 Sec#79/231 |
| BPS | 13,793 KRW | KR#757/2,405 Sec#51/231 |
Company Info
CMG Pharmaceutical, established in 2001, merged Celltrate Pharm Korea in 2008 and now primarily focuses on the research, development, production, and sales of pharmaceuticals and health functional foods. The company applies oral disintegrating films, leveraging its core STARFILM Technology, to incrementally modified drugs and is expanding its product portfolio into new business sectors like anti-cancer drugs, anti-aging, and ophthalmology. CMG Pharmaceutical is actively pursuing revenue growth and market share expansion through new drug development, facilitated by US FDA product approvals and technology exports. The company is headquartered in Gangnam-gu, Seoul.